Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101. Read more about Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.
Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Read more about Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.
Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population. Read more about Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population.
Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast. Read more about Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT). Read more about The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).
Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. Read more about Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.
Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Read more about Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.
REACT: A feasibility study to test the integration of a cancer registry early case ascertainment process via electronic pathology reporting with an online clinical trial matching tool. Read more about REACT: A feasibility study to test the integration of a cancer registry early case ascertainment process via electronic pathology reporting with an online clinical trial matching tool.
Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Read more about Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.
Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. Read more about Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer.
